How GW7647 can Save You Time, Stress, and Money.
The decrease in paclitaxel CL observed during the presence of zosuquidar triggered a boost in time that the plasma paclitaxel focus remains above 0.1 mol L−one, which is known being a marker of both equally toxicity (neutropenia) and efficacy [one]. Even though the impact of zosuquidar to the toxicity of the clinically utilized dose of paclitaxel